PXMD [NASD]
PaxMedica, Inc.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand10.02M Perf Week-13.40%
Market Cap25.02M Forward P/E- EPS next Y- Insider Trans- Shs Float0.66M Perf Month-30.96%
Income- PEG- EPS next Q- Inst Own- Short Float59.89% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.05 Perf Half Y-
Book/sh-1.17 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.04 - 10.48 Perf YTD-48.68%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-75.95% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low23.53% ATR1.09
Employees2 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility26.77% 28.57%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.08 Prev Close2.57
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume7.55M Price2.52
Recom- SMA20-24.87% SMA50-26.71% SMA200-26.71% Volume624,807 Change-1.95%
Aug-26-22 09:50AM
08:00AM
Aug-24-22 03:27PM
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Derby MichaelExecutive ChairmanAug 30Buy5.2595,000498,7507,336,745Sep 01 04:06 PM
TardiMed Sciences LLC10% OwnerAug 30Buy5.2595,000498,7507,336,745Sep 01 04:07 PM